The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation.

AUTOR(ES)

Muller, A J

RESUMO

The mRNA encoding the chimeric BCR/ABL oncogene, which is transcribed from the Philadelphia chromosome in human chronic myelogenous leukemia, has a 5' noncoding sequence greater than 500 bases in length which is highly GC rich and contains a short open reading frame. This untranslated sequence has a dramatic inhibitory effect upon translational efficiency in vitro. However, when BCR/ABL message is expressed in certain cell types such as the NIH 3T3 cell line, the 5' noncoding region has little inhibitory effect on translational efficiency.

Documentos Relacionados

• BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
• The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
• In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
• Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function.